Quick Read SummaryThis article explores how real-world evidence (RWE) is transforming prostate cancer treatment, complementing traditional randomized controlled trials (RCTs). It discusses a major observational study comparing apalutamide and enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC), showing a 23% lower mortality risk with apalutamide at 24 months. The piece emphasizes that RWE provides valuable context on long-term outcomes, adherence, and patient diversity but must be rigorously designed to avoid bias. It also highlights how clinicians can integrate RWE with patient-specific factors to personalize therapy and improve shared decision-making.
|
In an important new sponsored article published October 10, 2025, radiation oncologists Angela Jia, MD, PhD, and Daniel E. Spratt, MD, argue that real-world evidence (RWE) is increasingly reshaping how clinicians make treatment decisions in prostate cancer, especially in metastatic settings.
The piece highlights how RWE can complement but not replace randomized controlled trials (RCTs), providing deeper insight into treatment patterns, clinical decision‑making, and long-term outcomes in real-world settings. It centers on data about apalutamide (ERLEADA®) in metastatic castration‑sensitive prostate cancer (mCSPC), including an extensive observational study comparing it to enzalutamide.
In this article, I’ll summarize the key findings, place them into a broader context, and explore what the implications might be for prostate cancer patients, clinicians, and the evolution of prostate cancer care.
From Clinical Trials to Real Wisdom: Why RWE Matters
The limits of eligibility criteria and controlled clinical trials
RCTs remain the gold standard for establishing efficacy, but their eligibility criteria often skew toward younger, healthier patients with fewer comorbidities. As Drs. Jia and Spratt point out, “patients don’t walk into a clinic like perfect pegs that fit into trial eligibility criteria.”
Because of that, trial populations may poorly represent the diversity seen in clinical practice. RWE helps fill this gap by reflecting treatment outcomes in prostate cancer patients who would not have qualified for those trials.
RWE as a complementary, not competing, source of insight
The authors suggest that RWE should augment evidence derived from RCTs, rather than replace it. Well‑designed real‑world studies can explore comparative effectiveness, adherence, safety in underrepresented subgroups, and therapeutic performance over long-term periods.
In other words, RWE offers a window into how therapies perform in real-world settings, particularly across heterogeneous patient populations.
When Real World Meets Metastatic Hormone-Sensitive Prostate Cancer (mCSPC)
The RCT foundation: Apalutamide’s proven benefit
The sponsored article recounts key results from the phase 3 TITAN trial in mCSPC, in which ERLEADA® (apalutamide) added to androgen deprivation therapy (ADT) reduced the risk of death by 35% (hazard ratio 0.65) versus ADT alone. It also cut the risk of radiographic progression or death by 52%. Common side effects in that trial included rash, hot flashes, hypertension, arthralgia, and pruritus.
These RCT data established apalutamide’s role in metastatic hormone-sensitive prostate cancer, but left open some critical practical questions that RWE can help address.
The head-to-head real-world comparison: Apalutamide vs Enzalutamide
One of the more compelling parts of the writing is a real-world study involving nearly 4,000 patients with mCSPC, comparing outcomes between those starting apalutamide and those on enzalutamide. In that analysis, apalutamide was associated with a 23% lower risk of death at 24 months compared to enzalutamide.
Notably, the authors highlight methodological strengths: the study used a pre-specified protocol, a pre-defined primary endpoint (OS at 24 months), power calculations, and propensity score weighting (IPTW) to adjust for baseline differences and emulate the designs of controlled trials. STAT
Yet, they also acknowledge limitations: the possibility of miscoded, misclassified, or missing data, and that only documented covariates could be adjusted. The study is anchored at 24 months rather than over full follow-up, and it did not assess safety comparisons between the two ARIs. STAT+1
Still, this real-world finding offers clinicians another data point when choosing between androgen receptor inhibitors (ARIs) in mCSPC.
Bridging to mHSPC insights and big data trends
While the article focuses on mCSPC, the ecosystem of RWE is rapidly expanding across metastatic hormone-sensitive prostate cancer (mHSPC) as well. For example, a recent real-world “big data” analysis by the PIONEER+ group examined nearly 70,000 men with mHSPC across Europe and North America. That data suggested shifts in treatment patterns over time, influenced by age and comorbidities.
Additionally, prospective real-world studies like the OPTYX trial are collecting long-term data on other therapies like relugolix, aiming to chart adherence, safety, and outcomes in advanced prostate cancer settings.
These evolving RWE datasets may offer clinicians deeper context about real world data (RWD) trends, adherence challenges, and comparative performance of newer agents beyond just apalutamide.
Real-World Evidence in Action: Patient Stories & Clinical Decision
Real patients, real life
To humanize the clinical data, Jia and Spratt include the story of Bob Lane, diagnosed in 2014. He reflects on how treatment decisions, side effects, and the consistency of care were initially opaque, but apalutamide brought a new level of stability to his care. He says:
“ERLEADA, the inhibitor for my hormone-sensitive prostate cancer, has been an important part of my treatment … There’s a lot of life to live for me.”
Such narratives remind us that quality of life, tolerability, and adherence are integral to treatment decisions, not just survival curves.
Clinical decision-making in light of RWE
The authors argue that the physician’s role is to interpret and influence real-world clinical data for practicing clinicians. In other words, clinicians must synthesize RCTs, RWE, patient characteristics, and patient goals into shared decisions.
In practice, that might mean:
- Considering how a given patient’s comorbidities, age, or functional status compare to the RWE populations
- Recognizing that ARIs may perform differently in patients with renal disease, hepatic disease, or cardiac risk
- Weighing tolerability, side effects, and real-world treatment patterns (e.g., likely adherence)
- Discussing uncertainties inherent to observational data and being transparent with patients about what RWE can and cannot answer
When used thoughtfully, RWE empowers shared decision-making by giving patients and clinicians a bridge between controlled clinical trials and clinical practice.
Strengths, Cautions, and the Path Forward
The promise and challenges of RWE quality
Strong RWE analysis requires rigorous design: pre-specification, transparency, controlling confounding, and clear endpoints. Poorly done real-world studies risk misleading conclusions. The authors emphasize that quality matters; substandard RWE could erode confidence in the entire field.
Other challenges include:
- Incomplete data capture, missing variables
- Unmeasured confounding
- Bias in data collection or recording
- Differences in follow-up times
- Difficulty in reliably capturing side effects or safety data
Thus, each RWE study must be scrutinized critically.
Integration into evidence hierarchies
As RWE grows, the question becomes: how should it be integrated into clinical guidelines, regulatory decisions, and standard care pathways? Some proposals include hybrid trial–observational designs, embedding RWE in prospective protocol frameworks, or using RWE to trigger prospective validation trials.
Personalization and predictive inference
The next frontier involves merging RWE with genomic, imaging, and biomarker data to tailor therapy choices for specific subpopulations. As real-world registries grow more granular, clinicians may one day ask: “What happened to patients like me, with similar biomarkers and comorbidities?”
In prostate cancer care, where biomarker-driven decisions (e.g., DNA repair gene mutations for PARP inhibitors) are gaining traction, RWE might help define real-world subgroups that respond best. source
Longer-term outcomes and evolving endpoints
While short-term survival is essential, real-world studies can extend beyond the 2- or 5-year mark to examine long-term outcomes, durable remissions, late toxicity, secondary malignancies, functional status, and quality of life.
Key Takeaways
| The article “How Real-World Evidence Is Empowering Treatment Decisions in Prostate Cancer” argues that RWE can refine treatment decisions, especially in metastatic settings, by offering insight beyond what RCTs alone can provide. |
| The RWE head-to-head study comparing apalutamide and enzalutamide in mCSPC, which shows a 23% lower mortality risk at 24 months in favor of apalutamide, is a highlight, though it carries limitations typical of observational designs. |
| RWE should be viewed as a valuable partner to controlled clinical trials, not a replacement, provided RWE is conducted with sufficient rigor. |
| Clinicians must interpret RWE in context, integrating it with patient-specific factors, safety profiles, and patient goals to guide clinical decision making and shared planning. |
| Future directions point to deeper integration of RWE with biomarker data, enhancement of real-world registries, and longer-term outcomes to better mirror prostate cancer outcomes in everyday settings. |
